Your Messages Inbox
Your Article Summary
See Latest ArticlesAbbotts XIENCE V Continues to Outperform TAXUS with Sustained Clinical Advantages and Impressive Long-Term Safety Results in SPIRIT III Trial
Abbott, 09/22/09
Long–term data presented from the SPIRIT III pivotal U.S. clinical trial demonstrated that the observed clinical advantages of Abbott's market–leading XIENCE V Everolimus Eluting Coronary Stent System continued to increase as compared to the TAXUS Express2 Paclitaxel–Eluting Coronary Stent System. At three years, XIENCE V demonstrated a 43 percent reduction in the risk of major adverse cardiac events compared to TAXUS (9.1 percent for XIENCE V vs. 15.7 percent for TAXUS, p–value=0.003)*.
Today in Drug Trials...keeping you current
Receive free subspecialty "5-minute updates" via email
Reduction of biofilm formation with trisodium citrate in haemodialysis catheters: a randomized controlled trial
Nephrology Dialysis Transplantation, 12/07/09
Bayer HealthCare Pharmaceuticals Inc. Initiates Phase III Trial with Florbetaben PET Tracer for Imaging of Cerebral beta-Amyloid Plaques, a Pathological Hallmark of Alzheimer's Disease
Bayer HealthCare Pharmaceuticals, 12/07/09
Characterization of Baseline Methicillin-Resistant Staphylococcus aureus Isolates Recovered from Phase IV Clinical Trial for Linezolid
Journal of Clinical Microbiology, 12/03/09
Article Search
Sponsor